Overexpression of miR-203 increases the sensitivity of NSCLC A549/H460 cell lines to cisplatin by targeting Dickkopf-1 Retraction in /10.3892/or.2022.8461

Cheng,Ruirui; Lu,Chunya; Zhang,Guojun; Zhang,Guowei; Zhao,Guoqiang

doi:10.3892/or.2017.5505

Overexpression of miR-203 increases the sensitivity of NSCLC A549/H460 cell lines to cisplatin by targeting Dickkopf-1

Retraction in: /10.3892/or.2022.8461

Authors:
- Ruirui Cheng
- Chunya Lu
- Guojun Zhang
- Guowei Zhang
- Guoqiang Zhao
View Affiliations

Affiliations: Department of Respiratory Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, Henan 450001, P.R. China
Published online on: March 13, 2017 https://doi.org/10.3892/or.2017.5505
Pages: 2129-2136

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The number of new lung cancer cases diagnosed yearly is high, and the mortality rate has not substantially declined. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, and adenocarcinoma accounts for the largest proportion of NSCLC. Currently, platinum-based combined chemotherapy, particularly cisplatin (DDP) is still the main form of treatment for advanced NSCLC. However, cisplatin resistance often occurs in patients who receive chemotherapy. Previous studies offer various explanations for how miRNAs affect cisplatin resistance, but the underlying mechanism remains largely unknown. The present study was designed to focus on miR-203 and Dickkopf-1 (DKK1), investigating the potential mechanisms involved in cisplatin resistance in tissues of lung adenocarcinoma and A549/H460 cell lines. In DDP-sensitive NSCLC samples, miR-203 was expressed at a higher level when compared with this level in DDP-insensitive samples, while DKK1 mRNA was expressed at a relatively low level as indicated by qRT-PCR. Dual luciferase reporter assay revealed that DKK1 is a target gene of miR-203 in A549 and H460 cells. Upregulation of miR-203 reduced the IC50 value of cisplatin in the A549 and H460 cells by inhibiting cell growth and promoting cell apoptosis. Similar effects of tumor inhibition and cisplatin sensitization were verified in vivo. Further research showed that both overexpression of miR-203 and knockdown of DKK1 increased the sensitization to DDP with a lower IC50 value. Upon DKK1 knockdown, overexpression of miR-203 had no added effects on the sensitivity of the cells. In addition, miR-203 was unable to sensitize cells with DKK1 that lacked the 3' untranslated region (3'UTR). We conclude that miR-203 targets the 3'UTR of DKK1, and increases cisplatin sensitivity in A549/H460 cell lines.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
2	Zhang R, Zhang Y, Wen F, Wu K and Zhao S: Analysis of pathological types and clinical epidemiology of 6,058 patients with lung cancer. Zhongguo Fei Ai Za Zhi. 19:129–135. 2016.(In Chinese). PubMed/NCBI
3	Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, Stein KD, Alteri R and Jemal A: Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 66:271–289. 2016. View Article : Google Scholar : PubMed/NCBI
4	Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D'Amico TA, Dilling TJ, et al: NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4. 2016. J Natl Compr Canc Netw. 14:255–264. 2016.PubMed/NCBI
5	Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, et al: National comprehensive cancer network: Non-Small Cell Lung Cancer, version 6.2015. J Natl Compr Canc Netw. 13:515–524. 2015.PubMed/NCBI
6	Polo V and Besse B: Maintenance strategies in stage IV non-small-cell lung cancer (NSCLC): In which patients, with which drugs? Ann Oncol. 25:1283–1293. 2014. View Article : Google Scholar : PubMed/NCBI
7	Davidoff AJ, Tang M, Seal B and Edelman MJ: Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol. 28:2191–2197. 2010. View Article : Google Scholar : PubMed/NCBI
8	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
9	Hollis M, Nair K, Vyas A, Chaturvedi LS, Gambhir S and Vyas D: MicroRNAs potential utility in colon cancer: Early detection, prognosis, and chemosensitivity. World J Gastroenterol. 21:8284–8292. 2015. View Article : Google Scholar : PubMed/NCBI
10	Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, et al: MicroRNA expression profiles classify human cancers. Nature. 435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
11	Chen Y, Gao Y, Zhang K, Li C, Pan Y, Chen J, Wang R and Chen L: MicroRNAs as regulators of cisplatin resistance in lung cancer. Cell Physiol Biochem. 37:1869–1880. 2015. View Article : Google Scholar : PubMed/NCBI
12	Zhou P, Jiang N, Zhang GX and Sun Q: MiR-203 inhibits tumor invasion and metastasis in gastric cancer by ATM. Acta Biochim Biophys Sin. 48:696–703. 2016. View Article : Google Scholar : PubMed/NCBI
13	Zheng J, Wang F, Lu S and Wang X: LASP-1, regulated by miR-203, promotes tumor proliferation and aggressiveness in human non-small cell lung cancer. Exp Mol Pathol. 100:116–124. 2016. View Article : Google Scholar : PubMed/NCBI
14	Tang R, Zhong T, Dang Y, Zhang X, Li P and Chen G: Association between downexpression of MiR-203 and poor prognosis in non-small cell lung cancer patients. Clin Transl Oncol. 18:360–368. 2016. View Article : Google Scholar : PubMed/NCBI
15	Lin J, Lin Y, Fan L, Kuang W, Zheng L, Wu J, Shang P, Wang Q and Tan J: miR-203 inhibits cell proliferation and promotes cisplatin induced cell death in tongue squamous cancer. Biochem Biophys Res Commun. 473:382–387. 2016. View Article : Google Scholar : PubMed/NCBI
16	Wang C, Wang X, Liang H, Wang T, Yan X, Cao M, Wang N, Zhang S, Zen K, Zhang C, et al: miR-203 inhibits cell proliferation and migration of lung cancer cells by targeting PKCα. PLoS One. 8:e739852013. View Article : Google Scholar : PubMed/NCBI
17	Hu H, Xu Z, Li C, Xu C, Lei Z, Zhang HT and Zhao J: MiR-145 and miR-203 represses TGF-β-induced epithelial-mesenchymal transition and invasion by inhibiting SMAD3 in non-small cell lung cancer cells. Lung Cancer. 97:87–94. 2016. View Article : Google Scholar : PubMed/NCBI
18	Wang N, Liang H, Zhou Y, Wang C, Zhang S, Pan Y, Wang Y, Yan X, Zhang J, Zhang CY, et al: miR-203 suppresses the proliferation and migration and promotes the apoptosis of lung cancer cells by targeting SRC. PLoS One. 9:e1055702014. View Article : Google Scholar : PubMed/NCBI
19	You HY, Xie XM, Zhang WJ, Zhu HL and Jiang FZ: Berberine modulates cisplatin sensitivity of human gastric cancer cells by upregulation of miR-203. In Vitro Cell Dev Biol Anim. 52:857–863. 2016. View Article : Google Scholar : PubMed/NCBI
20	Ru P, Steele R, Hsueh EC and Ray RB: Anti-miR-203 upregulates SOCS3 expression in breast cancer cells and enhances cisplatin chemosensitivity. Genes Cancer. 2:720–727. 2011. View Article : Google Scholar : PubMed/NCBI
21	Liu Y, Gao S, Chen X, Liu M, Mao C and Fang X: Overexpression of miR-203 sensitizes paclitaxel (Taxol)-resistant colorectal cancer cells through targeting the salt-inducible kinase 2 (SIK2). Tumour Biol. 37:12231–12239. 2016. View Article : Google Scholar : PubMed/NCBI
22	Niehrs C: Function and biological roles of the Dickkopf family of Wnt modulators. Oncogene. 25:7469–7481. 2006. View Article : Google Scholar : PubMed/NCBI
23	Xia Y, He Z, Liu B, Wang P and Chen Y: Downregulation of Meg3 enhances cisplatin resistance of lung cancer cells through activation of the WNT/β-catenin signaling pathway. Mol Med Rep. 12:4530–4537. 2015.PubMed/NCBI
24	Jia X, Li N, Peng C, Deng Y, Wang J, Deng M, Lu M, Yin J, Zheng G, Liu H, et al: miR-493 mediated DKK1 down-regulation confers proliferation, invasion and chemo-resistance in gastric cancer cells. Oncotarget. 7:7044–7054. 2016.PubMed/NCBI
25	Huang Y, Yang X, Zhao F, Shen Q, Wang Z, Lv X, Hu B, Yu B, Fan J and Qin W: Overexpression of Dickkopf-1 predicts poor prognosis for patients with hepatocellular carcinoma after orthotopic liver transplantation by promoting cancer metastasis and recurrence. Med Oncol. 31:9662014. View Article : Google Scholar : PubMed/NCBI
26	Li S, Qin X, Guo X, Cui A, He Y, Wei S, Wang X and Shan B: Dickkopf-1 is oncogenic and involved in invasive growth in non small cell lung cancer. PLoS One. 8:e849442013. View Article : Google Scholar : PubMed/NCBI
27	Salim H, Zong D, Hååg P, Novak M, Mörk B, Lewensohn R, Lundholm L and Viktorsson K: DKK1 is a potential novel mediator of cisplatin-refractoriness in non-small cell lung cancer cell lines. BMC Cancer. 15:6282015. View Article : Google Scholar : PubMed/NCBI
28	Menezes ME, Devine DJ, Shevde LA and Samant RS: Dickkopf1: A tumor suppressor or metastasis promoter? Int J Cancer. 130:1477–1483. 2012. View Article : Google Scholar : PubMed/NCBI
29	Hirata H, Hinoda Y, Nakajima K, Kawamoto K, Kikuno N, Ueno K, Yamamura S, Zaman MS, Khatri G, Chen Y, et al: Wnt antagonist DKK1 acts as a tumor suppressor gene that induces apoptosis and inhibits proliferation in human renal cell carcinoma. Int J Cancer. 128:1793–1803. 2011. View Article : Google Scholar : PubMed/NCBI
30	Tung MC, Lin PL, Cheng YW, Wu DW, Yeh SD, Chen CY and Lee H: Reduction of microRNA-184 by E6 oncoprotein confers cisplatin resistance in lung cancer via increasing Bcl-2. Oncotarget. 7:32362–32374. 2016.PubMed/NCBI
31	Li W, Wang W, Ding M, Zheng X, Ma S and Wang X: MiR-1244 sensitizes the resistance of non-small cell lung cancer A549 cell to cisplatin. Cancer Cell Int. 16:302016. View Article : Google Scholar : PubMed/NCBI
32	Li JH, Luo N, Zhong MZ, Xiao ZQ, Wang JX, Yao XY, Peng Y and Cao J: Inhibition of microRNA-196a might reverse cisplatin resistance of A549/DDP non-small-cell lung cancer cell line. Tumour Biol. 37:2387–2394. 2016. View Article : Google Scholar : PubMed/NCBI
33	Fu WF, Chen WB, Dai L, Yang GP, Jiang ZY, Pan L, Zhao J and Chen G: Inhibition of miR-141 reverses cisplatin resistance in non-small cell lung cancer cells via upregulation of programmed cell death protein 4. Eur Rev Med Pharmacol Sci. 20:2565–2572. 2016.PubMed/NCBI
34	Wang Y, Ha M, Liu J, Li P, Zhang W and Zhang X: Role of BCL2-associated athanogene in resistance to platinum-based chemotherapy in non-small-cell lung cancer. Oncol Lett. 11:984–990. 2016.PubMed/NCBI
35	Qiu T, Zhou L, Wang T, Xu J, Wang J, Chen W, Zhou X, Huang Z, Zhu W, Shu Y, et al: miR-503 regulates the resistance of non-small cell lung cancer cells to cisplatin by targeting Bcl-2. Int J Mol Med. 32:593–598. 2013.PubMed/NCBI
36	Xu S, Huang H, Chen YN, Deng YT, Zhang B, Xiong XD, Yuan Y, Zhu Y, Huang H, Xie L, et al: DNA damage responsive miR-33b-3p promoted lung cancer cells survival and cisplatin resistance by targeting p21^WAF1/CIP1. Cell Cycle. 15:2920–2930. 2016. View Article : Google Scholar : PubMed/NCBI
37	Wang S, Liu F, Zhu J, Chen P, Liu H, Liu Q and Han J: DNA repair genes ERCC1 and BRCA1 expression in non-small cell lung cancer chemotherapy drug resistance. Med Sci Monit. 22:1999–2005. 2016. View Article : Google Scholar : PubMed/NCBI
38	Im JY, Lee KW, Won KJ, Kim BK, Ban HS, Yoon SH, Lee YJ, Kim YJ, Song KB and Won M: DNA damage-induced apoptosis suppressor (DDIAS), a novel target of NFATc1, is associated with cisplatin resistance in lung cancer. Biochim Biophys Acta. 1863:40–49. 2016. View Article : Google Scholar : PubMed/NCBI
39	Shen L, Yang M, Lin Q, Zhang Z, Miao C and Zhu B: SKA1 regulates the metastasis and cisplatin resistance of non-small cell lung cancer. Oncol Rep. 35:2561–2568. 2016.PubMed/NCBI
40	Qi K, Li Y, Li X, Lei X, Wang B, Zhang L and Chu X: Id4 promotes cisplatin resistance in lung cancer through the p38 MAPK pathway. Anticancer Drugs. 27:970–978. 2016. View Article : Google Scholar : PubMed/NCBI
41	Hu CF, Huang YY, Wang YJ and Gao FG: Upregulation of ABCG2 via the PI3K-Akt pathway contributes to acidic microenvironment-induced cisplatin resistance in A549 and LTEP-a-2 lung cancer cells. Oncol Rep. 36:455–461. 2016. View Article : Google Scholar : PubMed/NCBI
42	Sun W, Ma Y, Chen P and Wang D: MicroRNA-10a silencing reverses cisplatin resistance in the A549/cisplatin human lung cancer cell line via the transforming growth factor-β/Smad2/STAT3/STAT5 pathway. Mol Med Rep. 11:3854–3859. 2015.PubMed/NCBI
43	Wang Y, Wen L, Zhao SH, Ai ZH, Guo JZ and Liu WC: FoxM1 expression is significantly associated with cisplatin-based chemotherapy resistance and poor prognosis in advanced non-small cell lung cancer patients. Lung Cancer. 79:173–179. 2013. View Article : Google Scholar : PubMed/NCBI
44	Liu Y, Chen X, Gu Y, Zhu L, Qian Y, Pei D, Zhang W and Shu Y: FOXM1 overexpression is associated with cisplatin resistance in non-small cell lung cancer and mediates sensitivity to cisplatin in A549 cells via the JNK/mitochondrial pathway. Neoplasma. 62:61–71. 2015. View Article : Google Scholar : PubMed/NCBI
45	Wu HM, Jiang ZF, Ding PS, Shao LJ and Liu RY: Hypoxia-induced autophagy mediates cisplatin resistance in lung cancer cells. Sci Rep. 5:122912015. View Article : Google Scholar : PubMed/NCBI